Precision as the ranking strategy, not a constraint on it.
Diagnostics SEO is built around sensitivity, specificity and intended-use terms — content specific enough to survive regulatory review, because a vaguer, easier-to-rank claim is usually also one that would not clear review.
Claims here are bound tightly to what a test can actually detect — content that hedges or generalises to rank more easily usually fails regulatory review, so precision has to be the strategy from the outset, not a compliance edit applied afterward.
Overstating what a test detects is a regulatory risk here in a way it is not for most other pharmaceutical categories, so precision in wording matters more than usual. A generic pharmaceutical SEO checklist with the company name swapped in never accounts for that.
Research built around sensitivity, specificity and intended-use terms, content structured for precision over persuasion, and an audit of any claim broader than what the test can actually support.
Search content has to be as specific as the test itself — sensitivity, specificity, intended use — because a vaguer, easier-to-rank claim is usually also a claim regulatory review will not approve.
Diagnostics sites serve laboratory directors evaluating an assay and clinicians deciding when to order a test, and the two search in different languages. A laboratory search is technical — analytical sensitivity, sample type, throughput, platform compatibility, regulatory status. A clinical search is about the decision the result informs, phrased as a condition or a symptom. Trying to satisfy both on a single product page produces a page that reads as a specification sheet to one reader and as marketing to the other. Separating the technical assay page from the clinical use page lets each rank for its own vocabulary without either being diluted.
Sensitivity, specificity, limit of detection, cross-reactivity and the study conditions behind them are the substance of a diagnostics page. They are also what separates a page that ranks and holds its position from one that briefly appears and then drifts, because a laboratory that finds those numbers has a reason to return and to cite. Publishing them with the method and population that produced them, rather than as isolated percentages, is the difference between a claim and evidence — and under the in vitro diagnostic regulation the supporting documentation already exists, so the work is one of presentation rather than of generating anything new.
What comes up when planning search visibility for this category.
Variants of “diagnostic test sensitivity specificity”, almost never the broad category term an untargeted keyword plan starts from instead. This buyer is usually a lab director or clinical evaluator comparing an intended-use claim against a specific patient population, so the query already includes the clinical context a generic product page rarely addresses. Ranking for it means matching that context directly rather than the test name alone.
Search behaviour here centers on sensitivity, specificity and intended-use terms typed by lab directors and clinicians validating a test before adoption, not on the category name. The constraining factor here is regulatory: content that ranks by generalising a claim beyond what the test data supports creates review risk, so every page has to stay as precise as the underlying study.
Yes — see Diagnostics for the full range of platforms and content we build for this sector, including website builds, content architecture and ongoing platform work that sits alongside SEO. Most diagnostics clients start with one of these projects and add search strategy once the underlying site can support the clinical and regulatory content it depends on, rather than treating SEO as a standalone add-on.
Yes — the same sensitivity and specificity data can be structured for a clinical buyer scanning quickly and still stay fully accurate to the underlying study. We typically lead with the intended-use statement and key performance figures in plain language, then link through to the full methodology for anyone who wants the complete study detail, so neither audience has to wade through the other’s version.
Competitors can already obtain it from your instructions for use and your regulatory submissions, so the confidentiality argument protects very little. What withholding it does cost you is the laboratory evaluator who wanted to shortlist your assay and could not verify it without a sales call, and the search visibility that specific technical figures generate. The pragmatic line is to publish the performance characteristics that appear in your approved documentation and to keep pricing, roadmap and commercial terms behind a conversation.
Traffic that never seems to convert into the searches that actually matter for this category. Tell us what you have published and we will tell you what is missing. Tell us how "diagnostic test sensitivity specificity" performs for you today and we will tell you why.